RU2020132295A - Cpg амфифилы и их применения - Google Patents
Cpg амфифилы и их применения Download PDFInfo
- Publication number
- RU2020132295A RU2020132295A RU2020132295A RU2020132295A RU2020132295A RU 2020132295 A RU2020132295 A RU 2020132295A RU 2020132295 A RU2020132295 A RU 2020132295A RU 2020132295 A RU2020132295 A RU 2020132295A RU 2020132295 A RU2020132295 A RU 2020132295A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- amino acid
- protein
- acid sequence
- compound according
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 241000701806 Human papillomavirus Species 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Claims (25)
1. Соединение, состоящее из нуклеотидной последовательности 5'-TCGTCGTTTTG TCGTTTTGTCGTT-3' (SEQ ID NO:1), которая, на ее 5'-конце, связана или соединена при помощи линкера со следующим липидом:
или его солью,
где Х представляет собой О или S.
2. Соединение по п. 1, где нуклеотидная последовательность связана с липидом.
3. Соединение по п. 1 или 2, где все межнуклеозидные группы, соединяющие нуклеозиды в 5'-TCGTCGTTTTG TCGTTTTGTCGTT-3' (SEQ ID NO:1), представляют собой фосфоротиоаты.
4. Способ лечения рака у пациента, являющегося человеком, включающий введение пациенту соединения по п. 1 или 2, белка, включающего аминокислотную последовательность:
MHQKRTAMFQ DPQERPRKLP QLCTELQTTI HDIILECVYC KQQLLRREVY DFAFRDLCIV YRDGNPYAVG DKCLKFYSKI SEYRHYCYSL YGTTLEQQYN KPLCDLLIRC INGQKPLCPE EKQRHLDKKQ RFHNGRGRWT GRCMSCCRSS RTRRETQL (SEQ ID NO:2),
и белка, включающего аминокислотную последовательность:
MHGDTPTLHE YMLDLQPETT DLYGYGQLND SSEEEDEIDG PAGQAEPDRA HYNIVTFCCK CDSTLRLCVQ STHVDIRTLE DLLMGTLGIV CPICSQKP (SEQ ID NO:3).
5. Способ по п. 4, где рак является папилломавирус человека(HPV)-положительным.
6. Способ по п. 5, где рак является HPV 16 типа-положительным.
7. Способ по п. 4, где рак представляет собой плоскоклеточный рак головы или шеи.
8. Способ по п. 4, где пациент получает или получал химиотерапию препаратами платины.
9. Способ по п. 4, где соединение и белки, включающие аминокислотные последовательности SEQ ID NO:2 и SEQ ID NO:3, вводят одновременно.
10. Способ по п. 4, где соединение и белки, включающие аминокислотные последовательности SEQ ID NO:2 и SEQ ID NO:3, вводят последовательно.
11. Фармацевтическая композиция, включающая соединение по п. 1 или 2 и фармацевтически приемлемый носитель.
12. Фармацевтическая композиция по п. 11, отличающаяся тем, что композиция дополнительно включает белок, включающий аминокислотную последовательность:
MHQKRTAMFQ DPQERPRKLP QLCTELQTTI HDIILECVYC KQQLLRREVY DFAFRDLCIV YRDGNPYAVG DKCLKFYSKI SEYRHYCYSL YGTTLEQQYN KPLCDLLIRC INGQKPLCPE EKQRHLDKKQ RFHNGRGRWT GRCMSCCRSS RTRRETQL (SEQ ID NO:2),
и белок, включающий аминокислотную последовательность:
MHGDTPTLHE YMLDLQPETT DLYGYGQLND SSEEEDEIDG PAGQAEPDRA HYNIVTFCCK CDSTLRLCVQ STHVDIRTLE DLLMGTLGIV CPICSQKP (SEQ ID NO:3).
13. Набор, включающий (i) соединение по п. 1 или 2 и (ii) белок, включающий аминокислотную последовательность:
MHQKRTAMFQ DPQERPRKLP QLCTELQTTI HDIILECVYC KQQLLRREVY DFAFRDLCIV YRDGNPYAVG DKCLKFYSKI SEYRHYCYSL YGTTLEQQYN KPLCDLLIRC INGQKPLCPE EKQRHLDKKQ RFHNGRGRWT GRCMSCCRSS RTRRETQL (SEQ ID NO:2),
и белок, включающий аминокислотную последовательность:
MHGDTPTLHE YMLDLQPETT DLYGYGQLND SSEEEDEIDG PAGQAEPDRA HYNIVTFCCK CDSTLRLCVQ STHVDIRTLE DLLMGTLGIV CPICSQKP (SEQ ID NO:3).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637824P | 2018-03-02 | 2018-03-02 | |
| US62/637,824 | 2018-03-02 | ||
| PCT/US2019/020398 WO2019169328A1 (en) | 2018-03-02 | 2019-03-01 | Cpg amphiphiles and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020132295A true RU2020132295A (ru) | 2022-04-04 |
Family
ID=67805576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020132295A RU2020132295A (ru) | 2018-03-02 | 2019-03-01 | Cpg амфифилы и их применения |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210040159A1 (ru) |
| EP (1) | EP3758712A4 (ru) |
| JP (2) | JP2021516991A (ru) |
| KR (1) | KR20200140265A (ru) |
| CN (1) | CN112203663A (ru) |
| AU (1) | AU2019227988A1 (ru) |
| BR (1) | BR112020017778A2 (ru) |
| CA (1) | CA3092693A1 (ru) |
| IL (1) | IL277101B1 (ru) |
| MA (1) | MA52434A (ru) |
| MX (1) | MX2020009150A (ru) |
| RU (1) | RU2020132295A (ru) |
| SG (1) | SG11202008432XA (ru) |
| WO (1) | WO2019169328A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
| US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
| MX2023000041A (es) * | 2020-06-26 | 2023-03-10 | Elicio Therapeutics Inc | Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus. |
| WO2023022973A2 (en) * | 2021-08-16 | 2023-02-23 | Elicio Therapeutics, Inc. | Compositions containing polynucleotide amphiphiles and methods of use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6168778B1 (en) * | 1990-06-11 | 2001-01-02 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
| US8771702B2 (en) * | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
| US9090673B2 (en) * | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
| EP1776105A2 (en) * | 2004-07-18 | 2007-04-25 | Coley Pharmaceutical Group, Ltd | Methods and compositions for inducing innate immune responses |
| US20120087949A1 (en) * | 2008-12-19 | 2012-04-12 | University Of Florida Research Foundation, Inc. | Oligonucleotide micelles |
| US20120264810A1 (en) * | 2009-09-22 | 2012-10-18 | The University Of British Columbia | Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles |
| WO2012103038A2 (en) * | 2011-01-24 | 2012-08-02 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses therefor |
| AR095882A1 (es) * | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| CN107847505A (zh) * | 2014-09-11 | 2018-03-27 | 威登卓制药公司 | 多层脂质囊泡组合物及使用方法 |
-
2019
- 2019-03-01 SG SG11202008432XA patent/SG11202008432XA/en unknown
- 2019-03-01 CN CN201980028828.9A patent/CN112203663A/zh active Pending
- 2019-03-01 BR BR112020017778-4A patent/BR112020017778A2/pt unknown
- 2019-03-01 IL IL277101A patent/IL277101B1/en unknown
- 2019-03-01 RU RU2020132295A patent/RU2020132295A/ru unknown
- 2019-03-01 JP JP2020568945A patent/JP2021516991A/ja active Pending
- 2019-03-01 CA CA3092693A patent/CA3092693A1/en active Pending
- 2019-03-01 EP EP19761384.7A patent/EP3758712A4/en active Pending
- 2019-03-01 AU AU2019227988A patent/AU2019227988A1/en active Pending
- 2019-03-01 WO PCT/US2019/020398 patent/WO2019169328A1/en unknown
- 2019-03-01 MX MX2020009150A patent/MX2020009150A/es unknown
- 2019-03-01 MA MA052434A patent/MA52434A/fr unknown
- 2019-03-01 US US16/977,185 patent/US20210040159A1/en active Pending
- 2019-03-01 KR KR1020207028281A patent/KR20200140265A/ko unknown
-
2023
- 2023-12-28 JP JP2023222587A patent/JP2024045151A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020009150A (es) | 2020-12-11 |
| US20210040159A1 (en) | 2021-02-11 |
| EP3758712A4 (en) | 2021-12-15 |
| SG11202008432XA (en) | 2020-09-29 |
| EP3758712A1 (en) | 2021-01-06 |
| CA3092693A1 (en) | 2019-09-06 |
| MA52434A (fr) | 2021-01-06 |
| IL277101B1 (en) | 2024-05-01 |
| JP2021516991A (ja) | 2021-07-15 |
| AU2019227988A1 (en) | 2020-10-15 |
| CN112203663A (zh) | 2021-01-08 |
| WO2019169328A9 (en) | 2019-12-26 |
| IL277101A (en) | 2020-10-29 |
| WO2019169328A1 (en) | 2019-09-06 |
| KR20200140265A (ko) | 2020-12-15 |
| BR112020017778A2 (pt) | 2021-01-05 |
| JP2024045151A (ja) | 2024-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020132295A (ru) | Cpg амфифилы и их применения | |
| ES2909180T3 (es) | Vacunas de ácido nucleico | |
| JP2020530980A5 (ru) | ||
| Krieg | Therapeutic potential of Toll-like receptor 9 activation | |
| DE60029460T3 (de) | Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon | |
| Sun et al. | Interleukin-8 of Cynoglossus semilaevis is a chemoattractant with immunoregulatory property | |
| Schmidt et al. | Design and structural requirements of the potent and safe TLR-9 agonistic immunomodulator MGN1703 | |
| CN101137391B (zh) | 重组高效复合干扰素的用途 | |
| US20190216898A1 (en) | Interleukin Combination and Use Thereof | |
| EP2992000A1 (en) | Cyclic di-nucleotide induction of type i interferon | |
| JP2019506175A5 (ru) | ||
| KR101310511B1 (ko) | 흉선-특이성 단백질 | |
| JP2013532971A5 (ru) | ||
| JP2017529326A5 (ru) | ||
| JP2014532400A (ja) | 免疫賦活用の二本鎖ｒｎａ | |
| JP2010530362A5 (ru) | ||
| Byadgi et al. | The effect of TLR9 agonist CpG oligodeoxynucleotides on the intestinal immune response of cobia (Rachycentron canadum) | |
| Tharuka et al. | Molecular characterization and expression analysis of big-belly seahorse (Hippocampus abdominalis) interleukin-10 and analysis of its potent anti-inflammatory properties in LPS-induced murine macrophage RAW 264.7 cells | |
| EP3126501A1 (en) | Double-stranded rna conjugates and their use | |
| CN103088050B (zh) | 一种成熟人β防御素-2及其制备方法 | |
| MX2008015293A (es) | Composiciones bioactivas purificadas de hspe7. | |
| Cai et al. | Expression and purification of chicken beta interferon and its antivirus immunological activity | |
| CN104311672A (zh) | 一种具有肿瘤细胞靶向性的抑制剂多肽 | |
| WO2013097965A1 (en) | Triphosphate-containing double-stranded rna for immunostimulation | |
| JPWO2019169328A5 (ru) |